版本:
中国

BRIEF-Inotek Pharmaceuticals Corp posts Q1 loss per share $0.40

May 10 Inotek Pharmaceuticals Corp

* Inotek Pharmaceuticals Corporation reports first quarter 2017 financial results and operational highlights

* Inotek Pharmaceuticals Corp qtrly loss per share $0.40

* Inotek Pharmaceuticals Corp qtrly research and development expenses were $7.1 million, compared to $7.6 million for quarter ended March 31, 2016

* Inotek Pharmaceuticals - communicated with U.S. FDA regarding matrx-1 results, FDA in agreement that trial did not meet its primary efficacy endpoint

* Inotek Pharmaceuticals - is evaluating potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐